Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-10-31
2010-12-07
Lucas, Zachariah (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S004000, C435S005000
Reexamination Certificate
active
07846663
ABSTRACT:
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
REFERENCES:
patent: 6555311 (2003-04-01), Locarnini et al.
patent: 7422848 (2008-09-01), Bozdayi
patent: 2004/0194155 (2004-09-01), Delaney et al.
patent: 734831 (1998-06-01), None
patent: 2 309 379 (2001-12-01), None
patent: WO 98 21317 (1998-05-01), None
patent: WO 00/61758 (2000-10-01), None
patent: WO 01 57244 (2001-08-01), None
patent: WO 01/94559 (2001-12-01), None
patent: WO 03/066841 (2003-08-01), None
patent: WO 2004/031224 (2004-04-01), None
Database EMBL [Online] EBI; Hepatitis B virus mutante polymerase gene, Jun. 28, 2000, Yeh C. -T.: XP002510516, retrived from EBI Database accession No. AF156492.
Database EMBL [Online] EBI; Woodchuck hepatitis virus, Sep. 20, 2001, Yamamoto, T: XP002510517, retrived from EBI Database accession No. AF410856.
Miller et al. “Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408” 2001,JAIDS. , 27(5):450-8.
Stuyver et al. “Nomenclature for antiviral-resistant human hepatitus B virus mutations in the polymerase region” 2001,Hepatology, 33(3):751-7.
Villeneuve et al. “Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient” 2003,J. Hepa., 39(6):1085-9.
Xiong et al. “Resistance surveillance of HBeAg-chronic hepatitis B patients treated for 2 years with adefovir dipivoxi” 2003,J. Hepa., 38:182.
Bartholomeusz et al., 1997, “Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine,”International Antiviral News, vol. 5, No. 8: p. 123-124.
Estacio et al., 1988, “Nucleotide sequence of a hepatitis B virus genome of subtype adw isolated from a Philippino: Comparison with the reported three genomes of the same subtype,”Journal of Gastroenterology and Hepatology, vol. 3: p. 215-222.
Stuyver et al., 2001, “Nomenclature for Antiviral-Resistant Human Hepatitis B Virus Mutations in the Polymerase Region,”Hepatology, Williams and Wilkens, Baltimore, MD, US, vol. 33, No. 3: p. 751-757.
Database UniProt [Online], Jul. 1, 1993; “Protein P [Includes: DNA-directed DNA polymerase (EC<A HREF=” http://srs.ebi.ac.uk/srsbin/cgi-bin/wgetz?[enzyme-ECNumber:2.7.7.49]+-e”>2.7.7</A); RNA-directed DNA polymerase (EC < A HREF=”http://srs.ebi.ac.uk/srsbin/cig-bin/wgetz?[enzyme-ECNumber:2.7.7.49]+-e”>2.7.7.49</A>); Ribonuclease H (EC <A.
Gaillard et al., “Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity,” Antimicrob Agents Chemother. 46(4): 1005-1013, 2002.
Colonno et al., “Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection,” JID 184: 1236-45 2001.
Das et al., “Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC)”, J. Virol. 75(10): 4771-4779, 2001.
Delaney et al., “Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus,” Antimicrobial Agents Chemother 45(6): 1705-1713, 2001.
Ren and Nassal, “Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors,” J. Virol. 75(3): 1104-1116, 2001.
Yamanaka et al., “Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus,” Antimicrobial Agent Chem 43: 190-193, 1999.
Allen et al., “Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group,” Hepatology 27(6): 1670-1677, 1998.
Genovesi et al., “Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection,” Antimicrobial Agent Chem 42: 3209-3217, 1998.
Seifer et al., “In Vitro Inhibition of Hepadnavirus Polymerases by the Triphosphates of BMS-200475 and Lobucavir,” Antimicrobial Agent Chem 28; 3200-3208, 1998.
Xiong et al., “Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro,” Hepatology. 28(6): 1669-73, 1998.
Aye et al., “Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation,” J Hepatol. 26: 1148-53, 1997.
Bartholomeusz et al., “Clinical experience with famciclovir against hepatitis B virus,” Intervirology 40(5-6): 337-342 1997.
Bisacchi et al., “BMS-200475, a novel carbocyclic 2'-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro,” Bioorg. Med. Chem. Lit. 7: 127-132, 1997.
Innaimo et al., “Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus,” Antimicrobial Agent Chem 44: 1444-1448, 1997.
Main et al., “double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection,” J. Viral Hepatitis 3: 211-215, 1996.
Dienstag et al., “A preliminary trial of lamivudine for chronic hepatitis B infection,” New England J Med 333: 1657-1661, 1995.
Hendricks DA, et al., “Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay,” Am J Clin Pathol 104: 537-46, 1995.
Severini et al., “Mechanism of inhibition of duck hepatitis B virus polymerase by (-)- beta-L-2′,3′-dideoxy-3′-thiacytidine,” Antimicrobial Agents Chemother 39: 1430-1435, 1995.
Kruger et al., “Famciclovir treatment of hepatitis B recurrence after orthotopic liver transplantation-a pilot study [Abstract],” Hepatology 22: 219A, 1994.
Norder et al., “Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen,” (J. Gen. Virol. 74: 1341-1348, 1993.
Vere Hodge, “Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to peciclovir,” Antiviral Chem Chemother 4: 67-84, 1993.
Boyd et al., “Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals,” Antiviral Chem Chemother. 32: 358-363, 1987.
Summers and Mason, “Replication of the genome of a hepatitis B—like virus by reverse transcription of an RNA intermediate,” Cell 29: 403-415, 1982.
Ono et al., 2001, The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance, J. Clin. Invest 107(4):449-55.
Xiong et al., 2000, In vitro evaluati
Angus Peter William
Ayres Anna
Bartholomeusz Angeline Ingrid
Colledge Danielle
Locarnini Stephen Alister
Austin Health
Baker & Botts L.L.P.
Lucas Zachariah
Melbourne Health
LandOfFree
Hepatitis B viral variants with reduced susceptibility to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis B viral variants with reduced susceptibility to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis B viral variants with reduced susceptibility to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4156703